

Contents

Acknowledgments — V

Chapter 1

Introduction to computer-aided drug design (CADD) — 1

- 1.1 Introduction — 1
- 1.2 Drug discovery process — 2
 - 1.2.1 Discovery and development phase — 2
 - 1.2.2 Preclinical studies — 2
 - 1.2.3 Clinical trials — 4
- 1.3 Computer-aided drug design (CADD) — 6
 - 1.3.1 Structure-based drug designing (SBDD) — 6
 - 1.3.2 Ligand-based drug designing (LBDD) — 6
- 1.4 Historical perspective of CADD — 8
- 1.5 Applications of CADD in the drug discovery process — 10
 - 1.5.1 Drawing molecular structures and energy minimization — 10
 - 1.5.2 Performing molecular docking for studying the ligand–protein interaction — 10
 - 1.5.3 2D-QSAR modeling for the development of leads — 11
 - 1.5.4 3D-QSAR modeling — 12
 - 1.5.5 Homology modeling — 12
 - 1.5.6 Pharmacophore modeling and virtual screening — 12
 - 1.5.7 Molecular dynamics simulation — 12
 - 1.5.8 Prediction of absorption, distribution, metabolism, excretion, and toxicity (ADMET) parameters — 13
- References — 14

Chapter 2

Quantitative structure–activity relationship — 17

- 2.1 Quantitative structure–activity relationship (QSAR) — 17
- 2.2 Classification of QSAR methodologies — 19
 - 2.2.1 Based on the dimensions of descriptors used in the QSAR model — 19
 - 2.2.2 Based on the chemometric techniques employed for QSAR model generation — 24
 - 2.2.3 Based on the activity to be correlated in the QSAR model — 26
- 2.3 History and development of QSAR — 26
- References — 31

Chapter 3

Physicochemical parameters and QSAR — 34

- 3.1 Physicochemical parameters and QSAR — **34**
- 3.1.1 Lipophilicity parameters — **35**
- 3.1.2 Electronic parameters — **40**
- 3.1.3 Steric parameters — **45**
- References — **50**

Chapter 4

Quantitative models in QSAR — 53

- 4.1 Introduction — **53**
- 4.2 Hansch analysis — **54**
- 4.2.1 Importance of Hansch analysis in drug discovery — **58**
- 4.3 Craig plot — **59**
- 4.3.1 Importance of Craig plot in drug discovery — **60**
- 4.4 Topliss scheme — **61**
- 4.4.1 Topliss scheme I — **62**
- 4.4.2 Topliss scheme II — **65**
- 4.5 Free-Wilson analysis — **68**
- 4.5.1 The classical Free-Wilson model — **68**
- 4.5.2 The Fujita-Ban model (modified classical Free-Wilson model) — **71**
- 4.5.3 The relationship between Free-Wilson Analysis (FWA) and Hansch analysis (mixed approach) — **72**
- 4.6 Development of a 2D-QSAR model — **74**
- 4.6.1 Topological descriptors — **74**
- 4.7 Deriving a 2D-QSAR model — **76**
- References — **78**

Chapter 5

3D-QSAR in drug designing — 80

- 5.1 Introduction — **80**
- 5.2 Basic assumptions in 3D-QSAR modeling — **81**
- 5.3 Classification of 3D-QSAR methodology — **82**
- 5.3.1 Based on the chemometric technique used in the development of the QSAR equation — **82**
- 5.3.2 Based on the criterion of alignment — **83**
- 5.3.3 Based on the molecular modeling technique — **83**
- 5.4 Comparative molecular field analysis (CoMFA) — **83**
- 5.4.1 Methodology of CoMFA — **84**
- 5.5 Advantages of the CoMFA model — **94**
- 5.6 Limitations of the CoMFA model — **95**
- 5.7 Comparative molecular similar indices analysis (CoMSIA) — **96**

- 5.8 Advantages of the CoMSIA model — 97
- 5.9 Limitations of the CoMSIA model — 98
- 5.10 Other 3D-QSAR approaches — 99
- References — 103

Chapter 6

Statistical approaches used in the QSAR — 105

- 6.1 Introduction — 105
- 6.2 Linear regression analysis — 106
 - 6.2.1 Simple linear regression (SLR) — 106
 - 6.2.2 Multiple linear regression (MLR) — 112
- 6.3 Multivariate data analysis (MVDA) — 118
 - 6.3.1 Principal component analysis (PCA) — 118
 - 6.3.2 Partial least square (PLS) analysis — 122
 - 6.3.3 Genetic function approximation (GFA) — 127
 - 6.3.4 Pattern recognition or multivariate data classification procedures or cluster analysis — 128
- 6.4 Statistical parameters for the validation of the QSAR models — 133
 - 6.4.1 Internal validation parameters for the QSAR model — 133
 - 6.4.2 External validation of the QSAR model — 135
- References — 136

Chapter 7

Molecular and quantum mechanics in drug designing — 139

- 7.1 Introduction — 139
- 7.2 Molecular mechanics (MM) in drug design — 140
 - 7.2.1 Stretching and bending energy — 141
 - 7.2.2 Torsion energy — 142
 - 7.2.3 Nonbonding energy terms — 143
 - 7.2.4 Cross-bonding energy terms — 145
 - 7.2.5 Concept of force field in molecular mechanics (MM) — 145
- 7.3 Quantum mechanics (QM) in drug designing — 147
 - 7.3.1 Ab initio methods in the CADD — 148
 - 7.3.2 Density functional theory (DFT) in CADD — 151
 - 7.3.3 Semiempirical methods in the CADD — 153
- References — 157

Chapter 8

Energy minimization techniques in molecular modeling — 160

- 8.1 Introduction — 160
- 8.2 Concept of the local and global minima — 161
- 8.3 Derivative energy minimization methods — 163

8.3.1	First-order energy minimization methods —	166
8.3.2	Second-order energy minimization methods —	169
8.4	Nonderivative energy minimization methods (NDEM) —	173
8.4.1	Downhill simplex method of energy minimization —	173
8.4.2	The sequential univariate method for energy minimization —	176
8.5	Concept of global minima and bioactive conformer —	177
8.5.1	Global minima —	178
8.5.2	Bioactive conformers —	179
8.5.3	Molecular docking —	179
8.5.4	Molecular dynamics simulations —	179
	References —	180

Chapter 9

Molecular docking and drug-receptor interactions — 182

9.1	Introduction —	182
9.2	Theory of molecular docking —	183
9.2.1	Conformational search (search algorithms of the molecular docking) —	184
9.2.2	Scoring of the ligand-receptor binding —	192
9.3	Classification of molecular docking techniques —	198
9.3.1	Classification based on the flexibility of the molecules —	199
9.3.2	Classification based on types of molecules used for molecular docking —	203
9.4	Steps involved in the molecular docking (protein-ligand docking) —	204
9.4.1	Obtaining and optimizing the ligand structure —	205
9.4.2	Obtaining the structure of the target receptor —	206
9.4.3	Preparation of the protein —	206
9.4.4	Performing the molecular docking —	206
9.4.5	Analysis of the molecular docking results —	207
9.5	Some examples of molecular docking —	207
9.5.1	Agents acting on dihydrofolate reductase (DHFR) enzyme —	207
9.5.2	Agents acting on the HMG-CoA reductase —	209
9.5.3	Agents acting on HIV-protease —	212
9.5.4	Agents acting on acetylcholinesterase (AChE) —	214
	References —	217

Chapter 10

ADMET analysis in CADD — 221

10.1	Introduction —	221
10.2	Importance of ADME studies in CADD —	223
10.3	Absorption parameters of the drug molecule —	223
10.3.1	Partition coefficient/log <i>P</i> —	224

10.3.2	Acid–base dissociation constant (pK_a) —	225
10.3.3	Bioavailability (F) —	227
10.4	Distribution parameters of the drug molecule —	229
10.4.1	Apparent volume of distribution (V_d) —	229
10.4.2	Plasma protein binding —	230
10.4.3	CNS MPO score for the distribution of the drugs in the brain —	231
10.4.4	Blood–brain barrier (BBB) score —	232
10.5	Metabolism parameters of the drug molecule —	233
10.6	Excretion parameters of the drug molecule —	234
10.6.1	Clearance (CL) of the drug —	235
10.6.2	Plasma half-life of the drug ($t_{1/2}$) —	236
10.7	Toxicity aspects of the drug molecule —	237
10.8	Drug-likeness profile of the newly proposed drug molecule —	240
10.8.1	Lipinski's rule of five —	241
10.8.2	Muegge (Bayer) filter of drug-likeness —	241
	References —	244

Chapter 11

De novo drug designing approaches — 248

11.1	Introduction —	248
11.2	Classification of de novo drug designing —	251
11.2.1	Structure-based de novo drug designing —	251
11.2.2	Ligand-based de novo drug designing approach —	262
11.3	Advantages of de novo drug designing approaches —	265
11.4	Limitations of de novo drug designing approaches —	266
	References —	267

Chapter 12

Homology modeling — 269

12.1	Introduction —	269
12.2	Structure of a protein —	270
12.2.1	Primary structure of the protein —	271
12.2.2	Secondary structure of the protein —	271
12.2.3	Tertiary structure of the protein —	272
12.2.4	Quaternary structure of the protein —	273
12.3	Steps involved in the process of homology modeling —	274
12.3.1	Identification of the sequence of the amino acids of the query structure protein —	274
12.3.2	Identification of the template protein —	276
12.3.3	Alignment of the query protein with template protein structures —	277
12.3.4	Building the model of the query protein —	277
12.3.5	Refinement of the model developed —	283

- 12.3.6 Assessment and validation of the developed model — **287**
- 12.4 Applications of homology modeling in CADD — **289**
- 12.5 Advantages of homology modeling — **290**
- 12.6 Limitations of homology modeling — **290**
- References — **291**

Chapter 13

Pharmacophore mapping in computer-aided drug designing (CADD) — 293

- 13.1 Introduction — **293**
- 13.2 Historical perspective of the pharmacophore concept — **294**
- 13.3 Understanding the concept: pharmacophore — **296**
- 13.4 Types of pharmacophore modeling (mapping) — **297**
- 13.4.1 Ligand-based pharmacophore modeling — **297**
- 13.4.2 Structure-based pharmacophore modeling — **306**
- 13.5 Applications of the pharmacophore modeling approaches — **312**
- References — **313**

Chapter 14

Virtual screening approaches in the computer-aided drug designing — 316

- 14.1 Introduction — **316**
- 14.2 Chemical databases for the virtual screening in CADD — **316**
- 14.3 Classification of virtual screening — **318**
- 14.3.1 Structure-based virtual screening — **319**
- 14.3.2 Ligand-based virtual screening — **324**
- References — **334**

Index — 337